An engineered recombinase removes the HIV-1 provirus from patient-derived cells and reduces infection in humanized mice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Finzi, D. et al. Nat. Med. 5, 512–517 (1999).
Karpinksi, J.H.I., Chemnitz, J. & Buchholz, F. Nat. Biotechnol. 34, 401–409 (2016).
Archin, N.M. et al. Nature 487, 482–485 (2012).
Tebas, P. et al. N. Engl. J. Med. 370, 901–910 (2014).
Hütter, G. et al. N. Engl. J. Med. 360, 692–698 (2009).
Qu, X. et al. Nucleic Acids Res. 41, 7771–7782 (2013).
Ebina, H. et al. PLoS One 10, e0120047 (2015).
Hu, W. et al. Proc. Natl. Acad. Sci. USA 111, 11461–11466 (2014).
Kaminski, R. et al. Sci. Rep. 6, 22555 (2016).
Buchholz, F. & Stewart, A.F. Nat. Biotechnol. 19, 1047–1052 (2001).
Sarkar, I., Hauber, I., Hauber, J. & Buchholz, F. Science 316, 1912–1915 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Kim, M., Siliciano, R. Genome editing for clinical HIV isolates. Nat Biotechnol 34, 388–389 (2016). https://doi.org/10.1038/nbt.3531
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3531